CS
MRNA icon

Candriam SCA’s Moderna MRNA Stock Holding History

Candriam SCA’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6M Buy
309,196
+78,372
+34% +$4.05M 0.1% 193
2026
Q1 		$11.7M Buy
230,824
+1,826
+0.8% +$85.2K 0.06% 254
2025
Q4 		$6.75M Buy
228,998
+11,394
+5% +$310K 0.03% 332
2025
Q3 		$5.62M Sell
217,604
-3,382
-2% -$94.3K 0.03% 354
2025
Q2 		$6.1M Sell
220,986
-60,960
-22% -$1.61M 0.04% 321
2025
Q1 		$7.99M Sell
281,946
-330,916
-54% -$11.7M 0.05% 265
2024
Q4 		$25.5M Sell
612,862
-14,804
-2% -$708K 0.15% 142
2024
Q3 		$41.9M Buy
627,666
+145,614
+30% +$13.4M 0.24% 89
2024
Q2 		$57.2M Buy
482,052
+40,007
+9% +$5.06M 0.35% 63
2024
Q1 		$47.1M Buy
442,045
+79,001
+22% +$7.96M 0.3% 74
2023
Q4 		$36.1M Sell
363,044
-79,316
-18% -$6.67M 0.25% 92
2023
Q3 		$45.7M Buy
442,360
+92,221
+26% +$10.3M 0.32% 68
2023
Q2 		$42.5M Sell
350,139
-58,055
-14% -$7.74M 0.31% 76
2023
Q1 		$57.7M Sell
408,194
-11,933
-3% -$1.97M 0.4% 58
2022
Q4 		$75.5M Buy
420,127
+174,228
+71% +$28.5M 0.51% 38
2022
Q3 		$29.1M Buy
245,899
+110,425
+82% +$16.8M 0.2% 109
2022
Q2 		$19.4M Buy
135,474
+5,224
+4% +$747K 0.16% 145
2022
Q1 		$22.4M Sell
130,250
-39,014
-23% -$6.57M 0.15% 152
2021
Q4 		$43M Sell
169,264
-39,291
-19% -$11.5M 0.27% 92
2021
Q3 		$80.3M Sell
208,555
-98,459
-32% -$36.3M 0.55% 41
2021
Q2 		$72.1M Sell
307,014
-89,153
-23% -$15.9M 0.49% 44
2021
Q1 		$39.8M Hold
396,167
– – 0.33% 73
2020
Q4 		$41.4M Buy
+396,167
New +$40.1M 0.33% 73
2020
Q3 		– Sell
-285,834
Closed -$19.9M – 821
2020
Q2 		$18.6M Buy
+285,834
New +$15.7M 0.2% 130

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Candriam SCA's MRNA Position: Q2 2026 in Review

Candriam SCA increased its Moderna (MRNA) stake by 34% in Q2 2026, buying an estimated $4.05M and bringing the position to 309,196 shares worth $21.6M. The position accounts for 0.1% of the portfolio, ranked #193.

Candriam SCA first reported a position in MRNA in Q2 2020 and has held it in 24 quarters since. The position peaked at $80.3M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Candriam SCA held 309,196 shares of Moderna worth $21.6M as of Q2 2026.
  • Candriam SCA bought 78,372 Moderna shares in Q2 2026, an estimated $4.05M.
  • Moderna made up 0.1% of Candriam SCA's portfolio in Q2 2026, its #193 holding.
  • Candriam SCA first reported a position in Moderna in Q2 2020 and has held it in 24 quarters since.
  • Candriam SCA's Moderna position peaked at $80.3M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.